Motoyoshi Noike

Dioxygenases, key enzymes to determine the aglycon structures of fusicoccin and brassicicene, diterpene compounds produced by fungi.

Fusicoccin A and cotylenin A are structurally related diterpene glucosides and show a phytohormone-like activity. However, only cotylenin A induces the differentiation of human myeloid leukemia cells. Since the cotylenin A producer lost its ability to proliferate during preservation, a study on the relationship between structure and activity was carried out and a modified fusicoccin A with hydroxyl group at the 3-position showed a similar biological activity with that of cotylenin A. We then searched for an enzyme source that catalyzes the introduction of a hydroxyl group into the 3-position and found that brassicicene C, which is structurally related to fusicoccin A with hydroxyl group at the 3-position, was produced by Alternaria brassicicola ATCC96836. We recently cloned a brassicicene C biosynthetic gene cluster including the genes encoding fusicocca-2,10(14)-diene synthase and two cytochrome P450s, which were responsible for the formation of fusicocca-2,10(14)-diene-8β,16-diol. In this study, we report that a α-ketoglutarate dependent dioxygenase, the gene coding for which was located in the cluster, catalyzed a hydroxylation at the 3-position of fusicocca-2,10(14)-diene-8β,16-diol. On the other hand, a α-ketoglutarate-dependent dioxygenase, which had been identified in a fusicoccin A biosynthetic gene cluster, catalyzed the 16-oxidation of fusicocca-2,10(14)-diene-8β,16-diol to yield an aldehyde (8β-hydroxyfusicocca-1,10(14)-dien-16-al), although both dioxygenases had 51% amino acid sequence identity. These findings suggested that the dioxygenases played critical roles for the formation of the fusicoccin A-type and cotylenin A-/brassicicene C-type aglycons. Moreover, we showed that short-chain dehydrogenase/reductase located in the fusicoccin A biosynthetic gene cluster catalyzed the reduction of the aldehyde to yield fusicocca-1,10(14)-diene-8β,16-diol.

A peptide ligase and the ribosome cooperate to synthesize the peptide pheganomycin

Peptide antibiotics are typically biosynthesized by one of two distinct machineries in a ribosome-dependent or ribosome-independent manner. Pheganomycin (PGM (1)) and related analogs consist of the nonproteinogenic amino acid (S)-2-(3,5-dihydroxy-4-hydroxymethyl)phenyl-2-guanidinoacetic acid (2) and a proteinogenic core peptide, making their origin uncertain. We report the identification of the biosynthetic gene cluster from Streptomyces cirratus responsible for PGM production. Unexpectedly, the cluster contains a gene encoding multiple precursor peptides along with several genes plausibly encoding enzymes for the synthesis of amino acid 2. We identified PGM1, which has an ATP-grasp domain, as potentially capable of linking the precursor peptides with 2, and validate this hypothesis using deletion mutants and in vitro reconstitution. We document PGM1s substrate permissivity, which could be rationalized by a large binding pocket as confirmed via structural and mutagenesis experiments. This is to our knowledge the first example of cooperative peptide synthesis achieved by ribosomes and peptide ligases using a peptide nucleophile.

An enzyme catalyzing O-prenylation of the glucose moiety of fusicoccin A, a diterpene glucoside produced by the fungus Phomopsis amygdali.

Isoprenoids form the largest family of compounds found in nature. Isoprenoids are often attached to other moieties such as aromatic compounds, indoles/tryptophan, and flavonoids. These reactions are catalyzed by three phylogenetically distinct prenyltransferases: soluble aromatic prenyltransferases identified mainly in actinobacteria, soluble indole prenyltransferases mostly in fungi, and membrane‐bound prenyltransferases in various organisms. Fusicoccin A (FC A) is a diterpene glycoside produced by the plant‐pathogenic fungus Phomopsis amygdali and has a unique O‐prenylated glucose moiety. In this study, we identified for the first time, from a genome database of P. amygdali, a gene (papt) encoding a prenyltransferase that reversibly transfers dimethylallyl diphosphate (DMAPP) to the 6′‐hydroxy group of the glucose moiety of FC A to yield an O‐prenylated sugar. An in vitro assay with a recombinant enzyme was also developed. Detailed analyses with recombinant PAPT showed that the enzyme is likely to be a monomer and requires no divalent cations. The optimum pH and temperature were 8.0 and 50 °C, respectively. Km values were calculated as 0.49±0.037 μM for FC P (a plausible intermediate of FC A biosynthesis) and 8.3±0.63 μM for DMAPP, with a kcat of 55.3±3.3×10−3 s. The enzyme did not act on representative substrates of the above‐mentioned three types of prenyltransferase, but showed a weak transfer activity of geranyl diphosphate to FC P.

Molecular Breeding of a Fungus Producing a Precursor Diterpene Suitable for Semi-Synthesis by Dissection of the Biosynthetic Machinery

Many clinically useful pharmaceuticals are semi-synthesized from natural products produced by actinobacteria and fungi. The synthetic protocols usually contain many complicated reaction steps and thereby result in low yields and high costs. It is therefore important to breed microorganisms that produce a compound most suitable for chemical synthesis. For a long time, desirable mutants have been obtained by random mutagenesis and mass screening. However, these mutants sometimes show unfavorable phenotypes such as low viability and low productivity of the desired compound. Fusicoccin (FC) A is a diterpene glucoside produced by the fungus Phomopsis amygdali. Both FC and the structurally-related cotylenin A (CN) have phytohormone-like activity. However, only CN exhibits anti-cancer activity. Since the CN producer lost its ability to proliferate during preservation, a study on the relationship between structure and activity was carried out, and elimination of the hydroxyl group at position 12 of FC was essential to mimic the CN-like activity. Based on detailed dissection of the biosynthetic machinery, we constructed a mutant producing a compound without a hydroxyl group at position 12 by gene-disruption. The mutant produced this compound as a sole metabolite, which can be easily and efficiently converted into an anti-cancer drug, and its productivity was equivalent to the sum of FC-related compounds produced by the parental strain. Our strategy would be applicable to development of pharmaceuticals that are semi-synthesized from fungal metabolites.

Branched fatty acids inhibit the biosynthesis of menaquinone in Helicobacter pylori

Menaquinone (MK) is an essential compound because it is an obligatory component of the electron transfer pathway in microorganisms. In Escherichia coli, MK was shown to be derived from chorismate by eight enzymes, designated MenA–H.1,2 However, we have revealed that an alternative pathway (we named it the futalosine pathway; Figure 1)3–5 was operating in some microorganisms including Helicobacter pylori, which causes gastric carcinoma. As humans and some useful intestinal bacteria, such as lactobacilli, possess the classical pathway, and MK biosynthesis is essential for survival of microorganisms,4 the futalosine pathway is an attractive target for the development of specific anti-H. pylori drugs. In this study, we tried to obtain such compounds from metabolites produced by actinomycetes and fungi. To identify compounds that specifically inhibit the futalosin pathway, we developed a screening method. We previously showed that the MqnA–D genes in the futalosine pathway were essential for survival, as these gene-disrupted Streptomyces coelicolor strains required exogenously added MK for their growth. Therefore, a compound that inhibits the growth of S. coelicolor but does not inhibit its growth in the presence of MK would become a candidate. However, this assay method is laborious and the growth of S. coelicolor is too slow to screen a mass of samples. Therefore, we employed a paper disk-agar diffusion assay, which is based on the phenomenon that antibiotics will diffuse from a paper disk into an agar medium containing test organisms and form a growth-inhibitory zone. We used two kinds of Bacillus strains as test organisms. One was Bacillus subtilis and the other is B. halodurans C-125. By genome sequencing, the latter strain was shown to be quite similar to the former strain in terms of genome size, G+C content of genomic DNA and the physiological properties used for taxonomical identification.6 Moreover, the phylogenetic placement of B. halodurans C-125 based on 16S rDNA sequence analysis indicated that this organism is more closely related to B. subtilis than to other members of the genus Bacillus.6 For example, both strains showed similar MIC values against representative antibiotics except for clarithromycin (Table 1). The resistance to clarithromycin was probably caused by the presence of an ermD gene that encodes the ribosome-methylation enzyme in B. halodurans.7 However, judging from the genome database of these strains, B. subtilis and B. halodurans C-125 use the classical pathway and the futalosine pathway, respectively, for the biosynthesis of MK.6 These facts suggested that a compound inhibiting the biosynthesis of MK in the futalosine pathway specifically represses the growth of only B. halodurans C-12. Therefore, we first screened candidate compounds for their ability to specifically inhibit B. halodurans C-125 using a paper disk assay. We tested approximately 1800 culture broths (1000 actinomycetes broths and 800 fungi broths). Of these, approximately 300 culture broths (17%) formed growth-inhibitory zone against both B. subtilis and B. halodurans C-125. However, we found that two actinomycetes culture broths specifically inhibited the growth of B. halodurans C-125 (hit ratio, 0.1%) (Figure 2). Then we examined whether B. halodurans C-125 could recover from this inhibition when MK (0.1 mg ml 1) was added into the culture broth during liquid cultivation. The growth of B. halodurans C-125 was clearly inhibited in the presence of sample no. AF50404, but this inhibition was reversed by adding MK, even in the presence of sample no. AF50404. This result strongly suggested that sample no. AF50404 contained a compound that specifically inhibited the futalosine pathway. The other candidate (AF50573) also showed the same inhibitory phenotype as that of no. AF50404, but it gradually lost its activity, probably because of its instability. Therefore, we used sample no. AF50404 in further analyses.

Regiospecificities and Prenylation Mode Specificities of the Fungal Indole Diterpene Prenyltransferases AtmD and PaxD

ABSTRACT We recently reported the function of paxD, which is involved in the paxilline (compound 1) biosynthetic gene cluster in Penicillium paxilli. Recombinant PaxD catalyzed a stepwise regular-type diprenylation at the 21 and 22 positions of compound 1 with dimethylallyl diphosphate (DMAPP) as the prenyl donor. In this study, atmD, which is located in the aflatrem (compound 2) biosynthetic gene cluster in Aspergillus flavus and encodes an enzyme with 32% amino acid identity to PaxD, was characterized using recombinant enzyme. When compound 1 and DMAPP were used as substrates, two major products and a trace of minor product were formed. The structures of the two major products were determined to be reversely monoprenylated compound 1 at either the 20 or 21 position. Because compound 2 and β-aflatrem (compound 3), both of which are compound 1-related compounds produced by A. flavus, have the same prenyl moiety at the 20 and 21 position, respectively, AtmD should catalyze the prenylation in compound 2 and 3 biosynthesis. More importantly and surprisingly, AtmD accepted paspaline (compound 4), which is an intermediate of compound 1 biosynthesis that has a structure similar to that of compound 1, and catalyzed a regular monoprenylation of compound 4 at either the 21 or 22 position, though the reverse prenylation was observed with compound 1. This suggests that fungal indole diterpene prenyltransferases have the potential to alter their position and regular/reverse specificities for prenylation and could be applicable for the synthesis of industrially useful compounds.

Identification and analysis of the resorcinomycin biosynthetic gene cluster

Resorcinomycin (1) is composed of a nonproteinogenic amino acid, (S)-2-(3,5-dihydroxy-4-isopropylphenyl)-2-guanidinoacetic acid (2), and glycine. A biosynthetic gene cluster was identified in a genome database of Streptoverticillium roseoverticillatum by searching for orthologs of the genes responsible for biosynthesis of pheganomycin (3), which possesses a (2)-derivative at its N-terminus. The cluster contained a gene encoding an ATP-grasp-ligase (res5), which was suggested to catalyze the peptide bond formation between 2 and glycine. A res5-deletion mutant lost 1 productivity but accumulated 2 in the culture broth. However, recombinant RES5 did not show catalytic activity to form 1 with 2 and glycine as substrates. Moreover, heterologous expression of the cluster resulted in accumulation of only 2 and no production of 1 was observed. These results suggested that a peptide with glycine at its N-terminus may be used as a nucleophile and then maturated by a peptidase encoded by a gene outside of the cluster. Graphical abstract Biosynthetic gene cluster of resorcinomycin composed of (S)-2-(3,5-dihydroxy-4-isopropylphenyl)-2-guanidinoacetic acid and glycine was identified and characterized

Exploring Peptide Ligase Orthologs in Actinobacteria-Discovery of Pseudopeptide Natural Products, Ketomemicins.

We recently identified a novel peptide ligase (PGM1), an ATP-grasp-ligase, that catalyzes amide bond formation between (S)-2-(3,5-dihydroxy-4-methoxyphenyl)-2-guanidinoacetic acid and ribosomally supplied oligopeptides in pheganomycin biosynthesis. This was the first example of an ATP-grasp-ligase utilizing peptides as nucleophiles. To explore the potential of this type of enzyme, we performed a BLAST search and identified many orthologs. The orthologs of Streptomyces mobaraensis, Salinispora tropica, and Micromonospora sp. were found in similar gene clusters consisting of six genes. To probe the functions of these genes, we heterologously expressed each of the clusters in Streptomyces lividans and detected novel and structurally similar pseudotripeptides in the broth of all transformants. Moreover, a recombinant PGM1 ortholog of Micromonospora sp. was demonstrated to be a novel dipeptide ligase catalyzing amide bond formation between amidino-arginine and dipeptides to yield tripeptides; this is the first report of a peptide ligase utilizing dipeptides as nucleophiles.

A fungal prenyltransferase catalyzes the regular di-prenylation at positions 20 and 21 of paxilline

A putative indole diterpene biosynthetic gene cluster composed of eight genes was identified in a genome database of Phomopsis amygdali, and from it, biosynthetic genes of fusicoccin A were cloned and characterized. The six genes showed significant similarities to pax genes, which are essential to paxilline biosynthesis in Penicillium paxilli. Recombinants of the three putative prenyltransferase genes in the cluster were overexpressed in Escherichia coli and characterized by means of in vitro experiments. AmyG is perhaps a GGDP synthase. AmyC and AmyD were confirmed to be prenyltransferases catalyzing the transfer of GGDP to IGP and a regular di-prenylation at positions 20 and 21 of paxilline, respectively. AmyD is the first know example of an enzyme with this function. The Km values for AmyD were calculated to be 7.6 ± 0.5 μM for paxilline and 17.9 ± 1.7 μM for DMAPP at a kcat of 0.12 ± 0.003/s. Graphical Abstract An enzyme catalyzing the regular di-prenylation at positions 20 and 21 of paxilline was identified in Phomopsis amygdali and its property was characterized with recombinant

Structure and activity relationships of the anti-Mycobacterium antibiotics resorcinomycin and pheganomycin.

Tuberculosis (TB) caused by Mycobacterium tuberculosis infection is still threatening to human beings. It was reported that ~9 million people were infected and 1.4 million died from TB in 2011.1 Several antibiotics, such as isoniazid, rifampicin, pyrazinamide, streptomycin, ethambutol, kanamycin and ethionamide, were developed as anti-TB drugs and three to four of them are usually used in combination for chemotherapy.2 However, new antibiotics with high activity are still desirable because of the emergence of multidrug-resistant TB.1